94 related articles for article (PubMed ID: 33235319)
1. FGF401 and vinorelbine synergistically mediate antitumor activity and vascular normalization in FGF19-dependent hepatocellular carcinoma.
Huynh H; Prawira A; Le TBU; Vu TC; Hao HX; Huang A; Wang Y; Porta DG
Exp Mol Med; 2020 Nov; 52(11):1857-1868. PubMed ID: 33235319
[TBL] [Abstract][Full Text] [Related]
2. Lenvatinib inhibits angiogenesis and tumor fibroblast growth factor signaling pathways in human hepatocellular carcinoma models.
Matsuki M; Hoshi T; Yamamoto Y; Ikemori-Kawada M; Minoshima Y; Funahashi Y; Matsui J
Cancer Med; 2018 Jun; 7(6):2641-2653. PubMed ID: 29733511
[TBL] [Abstract][Full Text] [Related]
3. Discovery of 2,6-Naphthyridine Analogues as Selective FGFR4 Inhibitors for Hepatocellular Carcinoma.
Oh H; Kim J; Jung SH; Ha TH; Ahn YG; Nam G; Moon K; Singh P; Kim IS
J Med Chem; 2024 May; 67(10):8445-8459. PubMed ID: 38706130
[TBL] [Abstract][Full Text] [Related]
4. Metabolic regulator betaKlotho interacts with fibroblast growth factor receptor 4 (FGFR4) to induce apoptosis and inhibit tumor cell proliferation.
Luo Y; Yang C; Lu W; Xie R; Jin C; Huang P; Wang F; McKeehan WL
J Biol Chem; 2010 Sep; 285(39):30069-78. PubMed ID: 20657013
[TBL] [Abstract][Full Text] [Related]
5. FGF19-Based Mini Probe Targeting FGFR4 for Diagnosis and Surgical Navigation of Hepatocellular Carcinoma.
Cai J; Lian C; Lu Z; Shang Q; Wang L; Han Z; Gu Y
J Med Chem; 2024 Mar; 67(5):3764-3777. PubMed ID: 38385325
[TBL] [Abstract][Full Text] [Related]
6. Hypoxia-activated selectivity-improved anti-PKM2 antibody combined with prodrug TH-302 for potentiated targeting therapy in hepatocellular carcinoma.
Wang B; Qi FZ; Chen P; Qian LM; Su HS; Wang Y; Wang CH; Hou YX; Zhang Q; Li D; Chen ZS; Zhang SH
Int J Biol Sci; 2024; 20(5):1634-1651. PubMed ID: 38481819
[No Abstract] [Full Text] [Related]
7. Design and development of a robotized system coupled to µCT imaging for intratumoral drug evaluation in a HCC mouse model.
Bour G; Martel F; Goffin L; Bayle B; Gangloff J; Aprahamian M; Marescaux J; Egly JM
PLoS One; 2014; 9(9):e106675. PubMed ID: 25203629
[TBL] [Abstract][Full Text] [Related]
8. The anti-tumor effects of AZD4547 on ovarian cancer cells: differential responses based on c-Met and FGF19/FGFR4 expression.
Lee YY; Ryu JY; Cho YJ; Choi JY; Choi JJ; Choi CH; Sa JK; Hwang JR; Lee JW
Cancer Cell Int; 2024 Jan; 24(1):43. PubMed ID: 38273381
[TBL] [Abstract][Full Text] [Related]
9. Bevacizumab Augments the Antitumor Efficacy of Infigratinib in Hepatocellular Carcinoma.
Le TBU; Vu TC; Ho RZW; Prawira A; Wang L; Goh BC; Huynh H
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33321903
[TBL] [Abstract][Full Text] [Related]
10. Clinical impact of lenvatinib in patients with unresectable hepatocellular carcinoma who received sorafenib.
Chen YY; Wang CC; Liu YW; Li WF; Chen YH
PeerJ; 2020; 8():e10382. PubMed ID: 33240675
[TBL] [Abstract][Full Text] [Related]
11. The biology and rationale of targeting nectin-4 in urothelial carcinoma.
Heath EI; Rosenberg JE
Nat Rev Urol; 2021 Feb; 18(2):93-103. PubMed ID: 33239713
[TBL] [Abstract][Full Text] [Related]
12. Comparison of therapeutic outcomes of sorafenib and lenvatinib as primary treatments for hepatocellular carcinoma with a focus on molecular-targeted agent sequential therapy: A propensity score-matched analysis.
Tomonari T; Sato Y; Tani J; Hirose A; Ogawa C; Morishita A; Tanaka H; Tanaka T; Taniguchi T; Okamoto K; Sogabe M; Miyamoto H; Muguruma N; Uchida K; Masaki T; Takayama T
Hepatol Res; 2021 Apr; 51(4):472-481. PubMed ID: 33238074
[TBL] [Abstract][Full Text] [Related]
13. High throughput profiling of undifferentiated pleomorphic sarcomas identifies two main subgroups with distinct immune profile, clinical outcome and sensitivity to targeted therapies.
Toulmonde M; Lucchesi C; Verbeke S; Crombe A; Adam J; Geneste D; Chaire V; Laroche-Clary A; Perret R; Bertucci F; Bertolo F; Bianchini L; Dadone-Montaudie B; Hembrough T; Sweet S; Kim YJ; Cecchi F; Le Loarer F; Italiano A
EBioMedicine; 2020 Dec; 62():103131. PubMed ID: 33254023
[TBL] [Abstract][Full Text] [Related]
14. Anti-tumour effect of the fourth-generation chimeric antigen receptor T cells targeting CD133 against cholangiocarcinoma cells.
Sangsuwannukul T; Supimon K; Sujjitjoon J; Phanthaphol N; Chieochansin T; Poungvarin N; Wongkham S; Junking M; Yenchitsomanus PT
Int Immunopharmacol; 2020 Dec; 89(Pt B):107069. PubMed ID: 33242709
[TBL] [Abstract][Full Text] [Related]
15. hGC33-Modified and Sorafenib-Loaded Nanoparticles have a Synergistic Anti-Hepatoma Effect by Inhibiting Wnt Signaling Pathway.
Shen J; Cai W; Ma Y; Xu R; Huo Z; Song L; Qiu X; Zhang Y; Li A; Cao W; Zhou S; Tang X
Nanoscale Res Lett; 2020 Nov; 15(1):220. PubMed ID: 33242103
[TBL] [Abstract][Full Text] [Related]
16. The Combination of Icotinib Hydrochloride and Fluzoparib Enhances the Radiosensitivity of Biliary Tract Cancer Cells.
Zhu L; Zhu C; Wang X; Liu H; Zhu Y; Sun X
Cancer Manag Res; 2020; 12():11833-11844. PubMed ID: 33239915
[TBL] [Abstract][Full Text] [Related]
17. STAT3 enhances radiation-induced tumor migration, invasion and stem-like properties of bladder cancer.
Wang F; Ma X; Mao G; Zhang X; Kong Z
Mol Med Rep; 2021 Jan; 23(1):. PubMed ID: 33236137
[TBL] [Abstract][Full Text] [Related]
18. Targeted inhibition of FGF19/FGFR cascade improves antitumor immunity and response rate in hepatocellular carcinoma.
Tai DWM; Le TBU; Prawira A; Ho RZW; Huynh H
Hepatol Int; 2021 Oct; 15(5):1236-1246. PubMed ID: 34333737
[TBL] [Abstract][Full Text] [Related]
19. Dark and bright side of targeting fibroblast growth factor receptor 4 in the liver.
Gadaleta RM; Moschetta A
J Hepatol; 2021 Dec; 75(6):1440-1451. PubMed ID: 34364916
[TBL] [Abstract][Full Text] [Related]
20. Vinorelbine Improves the Efficacy of Sorafenib against Hepatocellular Carcinoma: A Promising Therapeutic Approach.
Ng WH; Soo KC; Huynh H
Int J Mol Sci; 2024 Jan; 25(3):. PubMed ID: 38338842
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
